Pharmacophore an International Research Journal
Pharmacophore
Submit Manuscript
Open Access | Published: 2023 - Issue 2

Assessment of Cytotoxic Activity Towards PC3 Cell Line of Peptide Esters of Galantamine: GAL-LEU and GAL-VAL Download PDF


, , , ,
Abstract

The current work's objective was to examine the cytotoxic activity of recently created peptide esters of Galantamine: GAL-LEU and GAL-VAL on prostate cancer PC3 cell lines. For the estimation of the cytotoxic effect of Galantamine derivatives, the MTT reduction assay was applied. PC3 cells were triplicate exposed separately to each of the peptide esters, applied in different concentrations (1.875 mМ ÷ 30 mМ). In the MTT test, the reduction of tetrazolium salt MTT resulted in the creation of formazan, whose absorbance was measured spectrophotometrically at wavelength 570 nm. The experimental results show that peptide ester GAL-LEU at 30 mM inhibits 55.36% of PC3 cell growth with an index of cell viability of 44.64 %. The lower antiproliferative effect of derivative GAL-VAL was proven by the fact that 30 mM inhibits 43.96 % of cell growth. The results showed that both of the tested esters had cytotoxic action against the PC3 cell line, but that GAL-LEU has a stronger antiproliferative impact than GAL-VAL (IC50 >30 mM), because of its lower value of IC50 = 30.8 mM.

Cite this article
Vancouver
Tsvetkova D, Vezenkov L, Ivanov T, Danalev D, Kostadinova I. Assessment of Cytotoxic Activity Towards PC3 Cell Line of Peptide Esters of Galantamine: GAL-LEU and GAL-VAL. Pharmacophore. 2023;14(2):111-9. https://doi.org/10.51847/1uNNypZfX2
APA
Tsvetkova, D., Vezenkov, L., Ivanov, T., Danalev, D., & Kostadinova, I. (2023). Assessment of Cytotoxic Activity Towards PC3 Cell Line of Peptide Esters of Galantamine: GAL-LEU and GAL-VAL. Pharmacophore, 14(2), 111-119. https://doi.org/10.51847/1uNNypZfX2

QR code:

Short Link:
Views: 268

Downloads: 49
Quick Access

Pharmacophore
ISSN: 2229-5402

Copyright © 2024 Pharmacophore, All rights are reserved and for all open access contents, the Creative Commons licensing terms apply.
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.